-
EP4332118
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4332118
| EP4332118 - NOVEL ANTI-CD5 CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL EXPRESSING SAME [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 02.02.2024 Database last updated on 02.09.2024 | |
| Former | The international publication has been made Status updated on 05.11.2022 | Most recent event Tooltip | 05.07.2024 | Change: Validation states | published on 07.08.2024 [2024/32] | 05.07.2024 | Change - extension states | published on 07.08.2024 [2024/32] | Applicant(s) | For all designated states Korea Research Institute of Bioscience and Biotechnology 125, Gwahak-ro, Yuseong-gu Daejeon 34141 / KR | [2024/10] | Inventor(s) | 01 /
KIM, Tae-Don Daejeon 34141 / KR | 02 /
CHO, Seona Daejeon 34141 / KR | 03 /
LEE, Sooyun Daejeon 34141 / KR | [2024/10] | Representative(s) | Dehns St. Bride's House 10 Salisbury Square London EC4Y 8JD / GB | [2024/10] | Application number, filing date | 22796130.7 | 27.04.2022 | [2024/10] | WO2022KR06009 | Priority number, date | KR20210055886 | 29.04.2021 Original published format: KR 20210055886 | [2024/10] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022231298 | Date: | 03.11.2022 | Language: | KO | [2022/44] | Type: | A1 Application with search report | No.: | EP4332118 | Date: | 06.03.2024 | Language: | EN | [2024/10] | Search report(s) | International search report - published on: | KR | 03.11.2022 | Classification | IPC: | C07K16/28, C12N5/0783, A61K35/17, A61P35/00 | [2024/10] | CPC: |
A61P35/00 (EP,KR);
C07K16/2896 (EP,KR,US);
A61K39/0011 (KR);
A61K39/395 (KR);
A61K39/4613 (EP,US);
A61K39/4631 (EP,US);
A61K39/464402 (US);
A61K39/464429 (EP);
A61P35/02 (US);
C07K14/7051 (KR,US);
C07K14/70596 (EP);
C07K16/30 (EP);
C12N15/86 (US);
C12N5/0646 (EP,KR,US);
A61K2039/505 (KR);
A61K2239/13 (US);
A61K2239/23 (EP);
C07K2317/622 (EP,KR,US);
C07K2319/02 (KR,US);
C07K2319/03 (KR,US);
C12N2510/00 (EP,KR);
C12N2740/15043 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/10] | Title | German: | NEUARTIGER CHIMÄRER ANTI-CD5-ANTIGENREZEPTOR UND IMMUNZELLE ZUR EXPRESSION DAVON | [2024/10] | English: | NOVEL ANTI-CD5 CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL EXPRESSING SAME | [2024/10] | French: | NOUVEAU RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE ANTI-CD5 ET CELLULE IMMUNITAIRE L'EXPRIMANT | [2024/10] | Entry into regional phase | 24.11.2023 | Translation filed | 24.11.2023 | National basic fee paid | 24.11.2023 | Search fee paid | 24.11.2023 | Designation fee(s) paid | 24.11.2023 | Examination fee paid | Examination procedure | 24.11.2023 | Examination requested [2024/10] | Fees paid | Renewal fee | 26.04.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2011250203 (KLITGAARD JOSEPHINE L K [DK], et al); | [A]KR20180002604 (ICELL GENE THERAPEUTICS LLC [US], et al); | [A]WO2020023561 (MAGENTA THERAPEUTICS INC [US]); | [A]US2020405811 (MAMONKIN MAKSIM [US], et al); | by applicant | KR20180002604 | KR102122546B |